Publications

2020

Sharlow, E.R., Koseoglu, M.M., Bloom, G.S.,and Lazo, J.S. The promise and perils of compound discovery screening with inducible pluripotent cell-derived neurons. Assay Drug Dev Technol. 18:97-103, 2020.
Porterfield, V., Khan, S., Foff, E., Koseoglu, M.M., Blanco, I.K., Jayaraman, S. Lien, E., McConnell, M.J., Bloom, G.S., Lazo, J.S., and Sharlow, E.R. A three-dimensional dementia model reveals spontaneous cell cycle reentry and a senescence-associated secretory phenotype. Neurobiol Aging. 90:125-134, 2020.
Aguilar-Sopeña, O., Hernández-Pérez, S., Alegre-Gómez, S., Castro-Sánchez, P., Iglesias-Ceacero, A., Lazo, J.S., and Roda-Navarro, P. Effect of pharmacological inhibition of the catalytic activity of phosphatases of regenerating liver in early T cell receptor signaling dynamics and IL-2 production. Int J Mol Sci. 5:21, 2020.

2019

Tasker, N.R., Rastelli, E.J., Blanco, I.K., Burnett, J.C., Sharlow, E.R.,Lazo, J.S., and Wipf, P. In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors. Org Biomol Chem. 17:2448-2466, 2019.
Koseoglu, M.M., Norambuena, A., Sharlow, E.R.,Lazo, J.S., and Bloom, G.S. Aberrant neuronal cell cycle re-entry: The pathological confluence of Alzheimer’s Disease and brain insulin resistance, and Its relation to cancer. J Alzheimer’s Dis. 67:1-11, 2019.
Lazo, J.S., Blanco, I.K., Tasker, N.R., Rastelli, E.J., Burnett, J.C., Garrott, S.R., Hart, D.J., McCloud, R.L., Hsu, K.-L., Wipf, P. and Sharlow, E.R. Next-generation cell-active inhibitors of the undrugged oncogenic PTP4A3 phosphatase. J Pharmacol Exptl Therap. 371:652-662, 2019.
Sharlow, E.R., Koseoglu, M.M., Bloom, G.S.,and Lazo, J.S. The promise and perils of compound discovery screening with inducible pluripotent cell-derived neurons. Assay Drug Dev Technol. In Press. doi: 10.1089/adt.2019.914.
Lazo, J.S. and Lau, A.F. What snaps your socks – A tribute to Dr. Raymond (Ray) W. Ruddon. The Pharmacologist. 61:184, 2019.
Lazo, J.S. The hubris and humility of cancer pharmacology in the post-immuno-oncology era. Pharmacol Res Perspec. 7:e00527, 2019

2018

McQueeney, K.E., Salamoun, J.E., Anh, J., Pekic, P., Blanco, I.K., Struckman, H., Sharlow, E.R., Wipf, P., and Lazo, J.S. PTP4A3 phosphatase regulates colorectal cancer cell migration, adhesion and Emilin 1 gene expression. FASEB J. 32: 5661-5673, 2018.
Johnston, P.A., Sen, M., Hua, Y., Camarco, D.P., Shun, T.Y., Lazo, J.S., and Grandis, J.R. High content imaging assays for IL-6-induced STAT3 pathway activation in Head and Neck cancer cell lines. Methods Mol Biol.1683:229-244, 2018.
Lazo, J.S. Refining radiation in the next century. Mol Cancer Therap. 17:332-335, 2018.
Lazo, J.S. Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches. F1000Res. 7:308, 2018

2017

McQueeney, K.E., Salamoun, J.M., Burnett, J.C., Barabutis, N., Pekic, P., Lewandowski, S.L., Llaneza, D.C., Cornelison, R., Bai, Y., Zhang, Z.-Y., Catravas, J.D., Landen Jr., C.N., Wipf, P., Lazo, J.S., and Sharlow, E.R. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget. 9:8223-8240.
Lazo, J.S., McQueeney, K.E. and Sharlow, E.R. New approaches to difficult drug targets: The phosphatase story. SLAS Discovery, 2472555217721142, 2017.
Bloom, G., Lazo, J.S. and Norambuena, A. Reduced brain insulin signaling: a seminal process in Alzheimer’s disease pathogenesis. Neuropharmacology. S0028-3908:30433-1, 2017.
Lazo, J.S., McQueeney, K.E., Birnett, J.C., Wipf, P., and Sharlow, E.R. Small targeting of PTPs in cancer. Int J Biochem Cell Biol S1357-2725:30237-6, 2017

2016

Sharlow, E.R., Leimgruber, S., Lira, A., McConnell, M.J., Norambuena, A., Bloom, G.S., Epperly, M.W., Greenberger, J.S., and Lazo, J.S. A small molecule screen exposes mTOR signaling pathway involvement in radiation-induced apoptosis. ACS Chem Biol. 11:1428-1437, 2016.
Johnston, P.A., Nguyen, M.M., Dar, J.A., Ai, J., Wang, Y., Masoodi, K.Z., Shun, T., Shinde, S., Camarco, D.P., Hua, Y., Huryn, D.M., Wilson, G.M., Lazo, J.S., Nelson, J.B., Wipf, P., and Wang Z. Development and implementation of a high-throughput high-content screening assay to identify inhibitors of androgen receptor nuclear localization in castration-resistant prostate cancer cells. Assay Drug Dev Technol. 14:226-239, 2016.
Salamoun, J.M., McQueeney, K.E., Patil, K., Geib, S.J., Sharlow, E.R., Lazo, J.S., and Wipf, P. Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor. Org Biomol Chem. 14:6398-6402, 2016.
LaPorte, M.G., Wang, Z., Colombo, R., Garzan, A., Peshkov, V.A., Liang, M., Johnston, P.A., Schurdak, M.E., Sen, M., Camarco, D.P., Hua, Y., Pollock, N.I., Lazo, J.S., Grandis, J.R., Wipf, P., and Huryn, D.M. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorg Med Chem Lett. 26: 3581-3585. 2016.
Lazo, J.S. and Sharlow, E.R. Drugging Undruggable Molecular Cancer Targets. Annu Rev Pharmacol Toxicol. 56: 23-40, 2016

2015

George Rosenker, K.M., Paquette, W.D., Johnston, P.A., Sharlow, E.R., Vogt, A., Bakan, A., Lazo, J.S., and Wipf, P. Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. Bioorg Med Chem. 23:2810-2818, 2015.
Johnston, P.A., Sen, M., Hua, Y., Camarco, D.P., Shun, T.Y., Lazo, J.S., Wilson, G.M., Resnick, L.O., LaPorte, M.G., Wipf, P., Huryn, D.M., and Grandis, J.R. HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 13:356-376, 2015.
Wang, H., Teriete, P., Hu, A., Raveendra-Panickar, D., Pendelton, K., Lazo, J.S., Eiseman, J., Holien, T., Misund, K., Oliynyk, G., Arsenian-Henriksson, M., Cosford, N.D., Sundan, A., and Prochownik, E.V. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. Oncotarget. 6:32380-32395, 2015.

2014

Cramer, J.M., Zimmerman, M.W., Thompson, T., Homanics, G.E., Lazo, J.S., and Lagasse, E. Deletion of Ptp4a3 reduces clonogenicity and tumor-initiation ability of colitis-associated cancer cells in mice. Stem Cell Res. 13:164-171, 2014.
Zimmerman, M.W., McQueeney, K.E., Isenberg, J.S., Pitt, B.R., Wasserloos, K.A., Homanics, G.E., and Lazo, J.S. PTP4A3 phosphatase promotes VEGF signaling and enables endothelial cell motility. J. Biol. Chem. 289:5904-5913, 2014.
Sharlow, E. R., Leimgruber, S., Murray, S., Lira, A., Sciotti, R.J., Hickman, M., Hudson, T., Leed, S., Caridha, D., Barrios, A. M., Close, D., Grogl, M., and Lazo, J.S. Auranofin is an apoptosis simulating agent with in vitro and in vivo anti-leishmanial activity. ACS Chem Biol. 9:663-672, 2014.
Johnston, P.A. Sen, M., Hua, Y., Camarco, D. Shun, T.Y., Lazo, J.S. and Grandis, J.S. High content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 12:55-79, 2014.
Sharlow, E.R., Wipf, P., McQueeney, K.E., Bakan, A. and Lazo, J.S. Investigational inhibitors of PTP4A3 phosphatases as antineoplastic agents. Expert Opin Invest Drugs. 23:661-673, 2014.

2013

Lazo, J.S., Sharlow, E.R., Epperly, M.W., Lira, A. Leimgruber, S., Skoda, E.M., Wipf, P. and Greenberger, J.S. Pharmacological profiling of phosphoinositide-3-kinase inhibitors as mitigators of ionizing radiation-induced cell death. J Pharmacol Exp Therap. 347:669-680, 2013.
Emert-Sedlak, L.A., Narute, P., Shu, S.T., Poe, J.A., Shi, H., Yanamala, N., Alvarado, J.J., Lazo, J.S., Yeh, J.I., Johnston, P.A., and Smithgall, T.E. Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol. 20:82-91, 2013.
Zimmerman, M.W., Homanics, G.E. and Lazo, J.S. Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One, 8:e58300, 2013.
Goff, J.P., Shields, D.S., Wang, H., Skoda, E.M., Sprachman, M.M., Wipf, P., Garapati, V.K., Atkinsosn, J., London, B., Lazo, J.S., Kagan, V., Epperly, M.W. and Greenberger, J.S. Evaluation of potential ionizing irradiation protectors and mitigators using clonogenic survival of human umbilical cord blood hematopoietic progenitor cells. Exptl. Hematol. 41:957-966, 2013.
Grogl, M., Hickman, M., Ellis, W., Hudson, T., Lazo, J.S., Sharlow, E.R., Johnson, J., Berman, J., Sciotti, R.J. Drug discovery algorithm for cutaneous leishmaniasis. Am J Trop Med Hyg. 88:216-221, 2013.
Lazo, J.S. President’s Corner: Comings and Goings. The Pharmacologist. 55:3, 2013.
International collaboration, a vital component of scientific progress. Pharmacology Matters. 6:5, 2013.

2012

Zellefrow, C.D., Sharlow, E.R., Epperly, M.W., Reese, C.E., Shun, T., Lira, A., Greenberger, J.S., and Lazo, J.S.. Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay. Radiation Res. 178:150-150, 2012.
McInnes, C., Estes, K., Baxter, M., Yang, Z., Farag, D. B., Johnston, P., Lazo, J.S., Wng. J. and Wyatt, M.D. Targeting subcellular localization through the Polo-Box domain: Non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Therap. 11:1683-1692, 2012.
Johnston, P.A., Shinde, S.N., Hua, Y, Shun, T. Y., Lazo, J.S., and Day, B.W. Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus. Assay Drug Dev Technol. 10:432-456, 2012.
Svilar, D., Dyavaiah, M., Brown, A.R., Tang, J., McDonald, P.R., Shun, T. Y., Wang, X-H., Lazo, J.S., Pollack, I.F., Begley, T.J. and Sobol, R. W. Alkylation sensitivity screens reveal a conserved cross-species functionome. Mol Cancer Res., 11:1683-1692, 2012.
Zhang, F., Rothermund, K, Gangadharan, S.B., Pommier, Y., Prochownik, E.V., and Lazo, J.S. Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target. Oncotarget. 3:998-1010, 2012.
Greenberger, J.S., Clump, D., Kagan, V., Bayir, H., Lazo, J.S., Wipf, P. Li, S., Gao, X., and Epperly, M.W. Strategies for discovery of small molecule radiation protectors and radiation mitigators. Frontiers in Oncology. 1:1-12, 2012.

2011

Shun, T.Y., Lazo, J.S., Sharlow, E.R., and Johnston, P.A. Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review. J Biomol Screen. 16: 1-14, 2011.

Vollmer, L.L., Jiménez, M., Camarco, D.P., Zhu, W., Daghestani, H.N., Balachandran, R., Reese, C.E., Lazo, J.S., Hukriede, N.A., Curran, D.P., Day, B.W., and Vogt, A. A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos. Mol Cancer Ther 10:994-1006, 2011.
Bravo-Altamirano, K., George, K.M., Frantz, M.C., Lavalle, C.R., Tandon, M., Leimgruber, S., Sharlow, E.R., Lazo, J.S., Wang, Q.J., and Wipf, P. Synthesis and structure-activity relationships of benzothienothiazepinone inhibitors of Protein Kinase D. ACS Med Chem Lett. 2:154-159, 2011.
Wang, Y., and Lazo, J.S. Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion. 31:818-827, 2011.
Kitchens ,C.A., McDonald, P.R., Shun, T.Y., Pollack, I.F., and Lazo, J.S. Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. J Pharmacol Exp Ther. 339:851-858, 2011.
Ma, C., Lazo, J.S., and Xie, X.Q. Compound acquisition and prioritization algorithm for constructing structurally diverse compound libraries. ACS Comb Sci. 13:223-231, 2011.
George, K.M., Frantz, M.C., Bravo-Altamirano, K., Lavalle, C.R., Tandon, M., Leimgruber, S., Sharlow, E.R., Lazo, J.S., Wang, Q.J., and Wipf, P. Design, synthesis, and biological evaluation of PKD inhibitors. 3:186-228, 2011.
Zhang, Y., Xie, Z., Wang, L., Schreiter, B., Lazo, J.S., and Gertsch J, and Xie, X.Q. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. Int Immunopharmacol. 11:1303-1310, 2011.
Sharlow, E.R., Mustata Wilson, G., Close, D., Leimgruber, S., Tandon, M., Reed, R.B., Shun, T.Y., Wang, Q.J., Wipf, P., and Lazo, J.S. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. PLoS One 6:e25134, 2011.
Lazo, J.S. Molecular Interventions (2001-2011): an experiment completed. Mol Interv 11:62, 2011.

images-1